Thomas Laedtke, MD
Endocrinology, Diabetes & Metabolism · Edina, MNNPI 1679532022
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,646 of the $38,982 with a category attached, or 91.4%. Novo Nordisk accounts for 60.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $17,149 and has fallen 97.2% since, to $482 in 2025. Among endocrinology, diabetes & metabolism clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $696.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$24K
- Bayer$14K
- Medtronic$1K
- Sanofi-aventis U.S. LLC$15
What the payments were for
- Speaking & faculty fees$35,64691%
- Travel & lodging$1,9205%
- Food & beverage$1,3513%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $23,557 |
| Bayer | 15 | $14,271 |
| Medtronic(2 entities) | 11 | $1,139 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$14,188
- Ozempic$10,440
- Tresiba$8,097
- RYBELSUS$3,875
- MINIMED 780G$535
- Enlite Sensor$108
How this compares
$38,982 in reported general payments places this provider in the 90th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 262 | $307,948 |
| MounjaroTirzepatide | 160 | $182,558 |
| Humalog Kwikpen U-200Insulin Lispro | 47 | $131,894 |
| JardianceEmpagliflozin | 119 | $119,577 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 79 | $90,471 |
| TrulicityDulaglutide | 56 | $51,732 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $39,140 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 277 | $31,225 |
| Teriparatide | 13 | $28,825 |
| Norditropin FlexproSomatropin | 17 | $27,500 |
| Humalog Kwikpen U-100Insulin Lispro | 104 | $26,909 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 52 | $20,730 |
| Testosterone | 74 | $18,973 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $17,701 |
| OmnitropeSomatropin | 14 | $17,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $23,557 | $316,403307 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $15 | $17,70122 claims |
| BayerKerendia | $14,271 | $8,28413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Edina
- John ChowEdina$3K
- Elizabeth HaglindEdina$3K
- Sarah Bou MalhamEdina$549
- Richard BergenstalSt Louis Park$595K
- Farha KhanCoon Rapids$349K
- Mark HolmSaint Cloud$318K
- Marjorie Ann MalbasRochester$222K
- Anders CarlsonSt Louis Park$163K
- Maria CaramoriMinneapolis$147K
- Irina BancosRochester$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.